Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants
Status:
Suspended
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
To assess pharmacokinetics parameters for nalbuphine after intravenous and intranasal
administration in infants. Also effect on pain score: Neonatal Infant Pain Score (NIPS) and
safety will be evaluated with summary of Adverse Events.
Inclusion criteria are: Infants 29 days-3 months, minimum Body weight 3.0 kg, Indications:
septical work up.
Exclusion criteria are: Infants who were born prematurely (before 37 weeks gestation), known
kidney or liver disease, known chronic illness.